KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue: 2018-2025

Historic Current Deferred Revenue for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Sep 2025 value amounting to $4.6 million.

  • Aurinia Pharmaceuticals' Current Deferred Revenue rose 6.92% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 6.92%. This contributed to the annual value of $11.0 million for FY2024, which is 128.59% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Current Deferred Revenue stood at $4.6 million, which was down 16.31% from $5.5 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Current Deferred Revenue high stood at $11.0 million for Q4 2024, and its period low was $190,000 during Q4 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Current Deferred Revenue value was $4.6 million (recorded in 2025), while the average stood at $5.0 million.
  • In the last 5 years, Aurinia Pharmaceuticals' Current Deferred Revenue spiked by 1,556.84% in 2022 and then decreased by 7.68% in 2024.
  • Quarterly analysis of 5 years shows Aurinia Pharmaceuticals' Current Deferred Revenue stood at $190,000 in 2021, then spiked by 1,556.84% to $3.1 million in 2022, then surged by 52.89% to $4.8 million in 2023, then spiked by 128.59% to $11.0 million in 2024, then increased by 6.92% to $4.6 million in 2025.
  • Its Current Deferred Revenue was $4.6 million in Q3 2025, compared to $5.5 million in Q2 2025 and $4.6 million in Q1 2025.